Cell Block Prep Method Modified for Molecular Studies
By LabMedica International staff writers Posted on 14 May 2018 |

Image: A microscopic appearance of cell blocks prepared by the HistoGel + ethanol (EtOH) method versus HistoGel-only and the EtOH-only methods. The insets in C and F illustrate excellent cytomorphologic preservation with this method (Photo courtesy of Memorial Sloan Kettering Cancer Center).
Biomarker testing is currently required to guide the selection of a growing number of targeted therapies in patients with a wide range of malignancies. Combined with increasing use of immunostaining for tumor diagnosis, this has substantially increased the demand for the amount of tissue in small specimens.
Recently, next-generation sequencing platforms have entered clinical practice. These platforms afford the ability to consolidate testing of multiple genes and types of alterations into a single platform; however, some next-generation sequencing platforms require substantially larger DNA input than standard molecular methods. For cytology specimens to remain a viable diagnostic modality in the era of personalized medicine, it is crucial for those specimens to consistently provide sufficient material for diagnostic and predictive ancillary studies.
Pathologists from Memorial Sloan Kettering Cancer Center (New York, NY, USA) tested multiple modifications of the cell block preparation protocol to identify a method with the greatest cell capture using split fine-needle aspirations (FNAs) and scrapes from fresh, surgically resected tumors (ex vivo samples). Ex vivo FNAs were prepared using a 25-gauge needle, and scrapes were prepared by gently scraping the cut surface of a tumor with a surgical blade. The team developed an improved HistoGel)-based cell block preparation method. Cellularity yield with the new versus the standard method was assessed in ex vivo split samples and in consecutive clinical fine-needle aspirates processed before and after.
The scientists reported that the key modification in the new method was pretreatment of the pelleted cells with 95% ethanol before the addition of HistoGel (HistoGel + ethanol method). In addition, they optimized the melting conditions of HistoGel and added a dark, inorganic marker to the cell pellets to highlight the desired level of sectioning during microtomy. Cell blocks from ex vivo split samples showed that the HistoGel + ethanol method yielded, on average, an 8.3-fold (range, 1–20) greater cellularity compared with the standard HistoGel-only method. After the switch from the standard HistoGel method to the modified method in their clinical practice, sufficiency of positive fine-needle aspirates for some molecular studies increased from 72% to 97%.
The authors concluded that a modification of the HistoGel-based cell block preparation method that leads to substantial improvement in cell recovery from FNA needle rinses compared with the standard HistoGel method. They showed the validation of this method both in ex vivo split samples and in routine clinical FNAs before and after the implementation of the new method in their laboratory. This protocol is simple and readily adoptable and leads to substantially increased sufficiency of FNA samples for molecular testing. The study was published in the April 2018 issue of the journal Archives of Pathology & Laboratory Medicine.
Related Links:
Memorial Sloan Kettering Cancer Center
Recently, next-generation sequencing platforms have entered clinical practice. These platforms afford the ability to consolidate testing of multiple genes and types of alterations into a single platform; however, some next-generation sequencing platforms require substantially larger DNA input than standard molecular methods. For cytology specimens to remain a viable diagnostic modality in the era of personalized medicine, it is crucial for those specimens to consistently provide sufficient material for diagnostic and predictive ancillary studies.
Pathologists from Memorial Sloan Kettering Cancer Center (New York, NY, USA) tested multiple modifications of the cell block preparation protocol to identify a method with the greatest cell capture using split fine-needle aspirations (FNAs) and scrapes from fresh, surgically resected tumors (ex vivo samples). Ex vivo FNAs were prepared using a 25-gauge needle, and scrapes were prepared by gently scraping the cut surface of a tumor with a surgical blade. The team developed an improved HistoGel)-based cell block preparation method. Cellularity yield with the new versus the standard method was assessed in ex vivo split samples and in consecutive clinical fine-needle aspirates processed before and after.
The scientists reported that the key modification in the new method was pretreatment of the pelleted cells with 95% ethanol before the addition of HistoGel (HistoGel + ethanol method). In addition, they optimized the melting conditions of HistoGel and added a dark, inorganic marker to the cell pellets to highlight the desired level of sectioning during microtomy. Cell blocks from ex vivo split samples showed that the HistoGel + ethanol method yielded, on average, an 8.3-fold (range, 1–20) greater cellularity compared with the standard HistoGel-only method. After the switch from the standard HistoGel method to the modified method in their clinical practice, sufficiency of positive fine-needle aspirates for some molecular studies increased from 72% to 97%.
The authors concluded that a modification of the HistoGel-based cell block preparation method that leads to substantial improvement in cell recovery from FNA needle rinses compared with the standard HistoGel method. They showed the validation of this method both in ex vivo split samples and in routine clinical FNAs before and after the implementation of the new method in their laboratory. This protocol is simple and readily adoptable and leads to substantially increased sufficiency of FNA samples for molecular testing. The study was published in the April 2018 issue of the journal Archives of Pathology & Laboratory Medicine.
Related Links:
Memorial Sloan Kettering Cancer Center
Latest Technology News
- Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
- Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
- Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read moreMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreMolecular Diagnostics
view channel
POC Oral Swab Test to Increase Chances of Pregnancy in IVF
Approximately 15% of couples of reproductive age experience involuntary childlessness. A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to... Read more
Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections
Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Blood Test Detects Up to Five Infectious Diseases at POC
Researchers have developed a prototype flow-through assay capable of detecting up to five different infections, with results that can be quickly analyzed and transmitted via a specialized smartphone app.... Read more
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Qiagen Acquires NGS Analysis Software Company Genoox
QIAGEN (Venlo, the Netherlands) has signed a definitive agreement to acquire Genoox (Tel Aviv, Israel), a provider of artificial intelligence (AI)-powered software that enables clinical labs to scale and... Read more
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more